Relationships Among Heart Rate, β-Blocker Dosage, and Prognosis in Patients With Coronary Artery Disease in a Real-World Database Using a Multimodal Data Acquisition System

Abstract

Increased heart rate (HR) is associated with cardiovascular events (CVE) not only in the general population and individuals with cardiovascular risk factors, 1-6 but also in patients with coronary artery disease (CAD). 7,8In patients with heart failure (HF), it is well established that low HR is associated with significantly lower rates of CVE. 9 Current evidence strongly supports the use of β-blockers (BBs) in HF patients with reduced left ventricular ejection fraction (HFrEF). Although it is known that higher doses of BBs are associated with significantly lower rates of CVE, 9-11 a low dose of β-blocker is also effective if

Impact of heart failure severity and major bleeding events after percutaneous coronary intervention on subsequent major adverse cardiac events

“…Data on PCI date, age, sex, physiological tests (body mass index [BMI], blood pressure, and pulse rate), laboratory tests (creatinine, estimated glomerular filtration rate [eGFR], and BNP), medications (antiplatelet, anticoagulant, and proton-pomp inhibitor), echocardiogram parameters (left ventricular ejection fraction [LVEF]), cardiac catheterization, and PCI treatment (target lesion and multivessel) were all directly collected and analyzed based on the Standardized Structured Medical Information eXchange Extended Storage. Additionally, the following data were collected: urgency (acute cardiac syndrome), past history (hypertension, diabetes mellitus [DM], dyslipidemia, hemodialysis, previous PCI, previous coronary artery bypass grafting [CABG], previous myocardial infarction [MI], previous stroke, atrial fibrillation [AF], malignancy, smoking, and peripheral artery disease [PAD]), and long-term prognosis (bleeding events, MACE, and all-cause death) [ 11 , 12 ]. This retrospective study included a total of 9690 consecutive patients who underwent PCI for acute coronary syndrome (ACS) or stable coronary artery disease between April 2014 and March 2020 in the participating hospitals, were registered in the CLIDAS database, and followed up for three years.…”

Hyperuricemia predicts increased cardiovascular events in patients with chronic coronary syndrome after percutaneous coronary intervention: A nationwide cohort study from Japan

“…In this study, hyperuricemia was defined as a SUA level ≥7.0 mg/dL for men or ≥6.0 mg/dL for women and/or taking urate-lowering drugs according to the previous studies (18)(19)(20)(21). CCS was defined as cases of PCI other than acute coronary syndrome (22). Hypertension was defined as a systolic blood pressure ≥140 mmHg, diastolic blood pressure ≥90 mmHg, or a medical treatment for hypertension at index PCI.…”

Sex Differences in Long-Term Outcomes in Patients With Chronic Coronary Syndrome After Percutaneous Coronary Intervention ― Insights From a Japanese Real-World Database Using a Storage System ―

“…CCS was defined as cases of PCI other than acute coronary syndrome. 18 The definition of CCS in the present study was almost identical to stable CAD with obstructive epicardial arteries because our database included patients who underwent PCI. Hypertension was defined as a systolic blood pressure ≥140 mmHg, diastolic blood pressure ≥90 mmHg, or medical treatment for hypertension at index PCI.…”

“…This was a retrospective multicenter observational study that included patients with CAD who underwent PCI at 7 hospitals between April 2013 and March 2019. 18 Patients with acute coronary syndrome and those without event data were excluded. The final study population was divided into 2 groups based on sex.…”